

Research Article

Size-Dependent Photodynamic Activity of Gold Nanoparticles Conjugate of Water Soluble Purpurin-18-*N*-Methyl-*D*-Glucamine

Byambajav Lkhagvadulam, Jung Hwa Kim, Il Yoon, and Young Key Shim

PDT Research Institute, School of Nano System Engineering, Inje University, Gimhae 621-749, Republic of Korea

Correspondence should be addressed to Il Yoon, yoonil71@inje.ac.kr and Young Key Shim, ykshim@inje.ac.kr

Received 23 July 2012; Accepted 23 August 2012

Academic Editor: Kristjan Plaetzer

Copyright © 2013 Byambajav Lkhagvadulam et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gold nanoparticles (GNPs) conjugates of water soluble ionic photosensitizer (PS), purpurin-18-*N*-methyl-*D*-glucamine (Pu-18-NMGA), were synthesized using various molar ratios between HAuCl₄ and Pu-18-NMGA without adding any particular reducing agents and surfactants. The PS-GNPs conjugates showed long wavelength absorption of range 702–762 nm, and their different shapes and diameters depend on the molar ratios used in the synthesis. *In vitro* anticancer efficacy of the PS-GNPs conjugates was investigated by MTT assay against A549 cells, resulting in higher photodynamic activity than that of the free Pu-18-NMGA. Among the PS-GNPs conjugates, the GNPs conjugate from the molar ratio of 1:2 (Au(III): Pu-18-NMGA) exhibits the highest photodynamic activity corresponding to bigger size (~60 nm) of the GNPs conjugate which could efficiently transport the PS into the cells than that of smaller size of the GNPs conjugate.

1. Introduction

Photodynamic therapy (PDT) is a promising noninvasive cancer treatment by using a combination of photosensitizer (PS), light, and oxygen [1–3]. For excellent photodynamic activity, PS should be penetrated into the tumor cells sufficiently [4]. Most of PSs are hydrophobic and thus locate preferentially in the lipid bilayers of organelle membranes in cancer cells. However, the hydrophobic nature of PSs makes them insoluble under physiological conditions and hinders to reach the accumulation in the tumor sites [5]. Therefore, for both hydrophobic and hydrophilic (amphiphilic) environments of PSs, introduction of water soluble PS with suitable carrier is a one potential method [6-8]. On the other hand, highly water soluble (hydrophilic) PSs allow poor cellular uptake based on a short pharmacological half-life which may have limit to penetrate through the tissue and cell membranes [9–11].

Nanoparticles (NPs) [12–14] are promising carrier system of PSs that could be protected from being uptaken by the reticuloendothelial system and extended the circulation time of NPs in the blood, and, finally, preferentially

accumulated in tumor sites through the so-called "enhanced permeability and retention (EPR)" effect [15-17]. Among the NPs, gold nanoparticles (GNPs) are highly efficient PDT drug delivery platform with good advantages based on their chemical inertness and minimum toxicity that has potential applications in biomedicine such as photothermal therapy (PTT) [18–21] of cancer, gene and drug delivery, biological imaging, and biosensing [22-26]. In addition, GNPs have large surface-to-volume ratios and easy tuning of the NPs size, resulting in penetration into tumor cells and intracellular localization at endosomes/lysosomes of the cells, and finally targeting at mitochondrial of cancer cells induces apoptosis to destroy the cancer cells [27-31]. It is noted that the size of the GNPs plays a big role in their uptake at the cellular level leading to different PDT activity. However, to the best of our knowledge, there are few reports for relationship between GNPs and its size effect on photodynamic activity [28].

Previously, we developed new synthesis of PS-GNPs conjugate using water soluble ionic purpurin-18-*N*-methyl-*D*glucamine (Pu-18-NMGA, PS1, Figure 1) and this conjugate showed better *in vitro* anticancer efficacy than that of free PS1 against A549 lung cancer cells [32].



FIGURE 1: Synthetic method of N-methyl-D-glucamine salt of purpurin-18 (Pu-18-NMGA, PS1).

In this paper, we have synthesized various sizes of PS-GNPs conjugates using a simple single-step synthesis from different molar ratios of HAuCl₄/PS1 without adding any particular reducing agents and surfactants, and showed size effect allowed different photodynamic activity results of the conjugates as an important factor for PDT. We evaluated *in vitro* anticancer efficacy of the PS-GNPs conjugates against A549 cells using MTT assay.

2. Materials and Methods

2.1. Materials. All reagents were purchased from Aldrich and used without further purification. All aqueous solutions were made using triply distilled water. All reactions were monitored by thin-layer chromatography (TLC) using Merck 60 silica gel F254 precoated (0.2 mm thickness) glass-backed sheets. Silica gel 60A (230–400 mesh, Merck) was used for column chromatography. The ¹H NMR spectra were obtained using a Varian spectrometer (500 MHz) at Biohealth Products Research Center (BPRC) at Inje University. The chemical shifts (δ) are given in parts per million (ppm) relative to tetramethylsilane (TMS, 0 ppm). High-resolution fast atom bombardment mass (HRFABMS) spectra were obtained with a Jeol JMS700 high-resolution mass spectrometer at the Daegu center of KBSI, Kyungpook National University, Korea.

The PS1 and PS-GNPs conjugates **2a–2e** were characterized by a combination analysis of ¹H-NMR and UV-vis spectroscopies, transmission electron microscopy (TEM), and infrared (IR) spectroscopy. UV-vis absorption spectra were recorded using a SCINCO S-3100 UV-vis spectrophotometer using 1 cm quartz cuvette. TEM images were performed on a JEOL, JEM 2011. A typical sample for TEM was prepared by drying of a drop of the solution at room temperature on a carbon-coated copper grid. IR spectra were measured on a Varian-640 FT-IR spectrometer. 2.2. Synthesis. Methyl pheophorbide-a (MPa) [33], purpurin-18 (Pu-18) [34], and *N*-methyl-*D*-glucamine salt of purpurin-18 (Pu-18-NMGA, PS1) [32] were prepared according to the procedures in literature, and all analytical data are identical with those in the literatures.

N-Methyl-D-Glucamine Salt of Purpurin-18 (Pu-18-NMGA, *PS***1**) [32]. To a solution of Pu-18 (56.4 mg, 0.1 mmol) in MeOH/CH₂Cl₂ (3:1, 10 mL), a solution of NMGA (39.0 mg, 0.2 mmol) in MeOH/water (1:2, 20 mL) was added and the mixture was stirred for 4 h. The organic solvents were evaporated under vacuum and the resulting aqueous solution was filtered through a membrane (20 μ m) and freeze-dried to give PS1. Yield: 68.0 mg (87%). UV-vis (water): λ , nm (log ε) 282 (0.34), 379 (0.55), 388 (0.58), 405 (0.61), 501 (0.13), 561 (0.11), 652 (0.28), 702 (0.21). ¹H NMR (500 MHz, CD₃OD, 25°C, TMS) δ, ppm 9.68 (1H, s, H-5), 9.39 (1H, s, H-10), 8.95 (1H, s, H-20), 8.69 (2H, s, H-NH gluc), 7.80 (1H, m, H-3¹), 6.24 and 6.12 (2H, dd, H-3²), 5.07 (1H, m, H-18), 4.49 (1H, m, H-17), 4.05 (2H, m, H-1 gluc), 3.83 (4H, m, OH-2,3,4,5 gluc), 3.69 (4H, m, H-2,3,4,5 gluc), 3.63 (3H, s, H-12), 3.48 (2H, m, H-8¹), 3.21 (3H, s, H-2¹), 3.18 (1H, m, OH-1 gluc), 3.07 (2H, dd, H-6 gluc), 3.03 (3H, s, H-7¹), 2.74 (3H, s, H-7 gluc), 2.46 (2H, m, H-17¹), 2.26 (3H, m, H-17²), 1.95 (3H, m, H-18¹), 1.83 (3H, d, H-8²), 1.69 (1H, br s, NH), 1.32 (1H, br s, NH). HRFABMS: calcd for $C_{40}H_{50}N_5O_{10}$ ([M + H]⁺) 760.3558, found 760.3554.

Synthesis of PS-GNPs Conjugates 2a-2e. The GNPs were synthesized according to the seed growth method [25] with some modifications. PS-GNPs conjugates 2a-2e were synthesized from different molar ratios between Au(III) and PS1 through reduction of chloroauric acid (HAuCl₄) with no use of reducing agent or surfactant.

Preparation of Seed Solution of PS-GNPs Conjugate. 0.002 M solution of PS1 (5 mL) was mixed with 0.001 M HAuCl₄



FIGURE 2: Synthetic method of PS-GNPs conjugates **2a–2e** with various molar ratios between gold and Pu-18-NMGA (*n* and *m* are molar ratios).



FIGURE 3: UV-vis spectra of (a) PS1 and PS-GNPs conjugates 2a-2e with various molar ratios between gold and Pu-18-NMGA in water (2a, Au:Pu-18-NMGA = 1 : 2; 2b, 1 : 4; 2c, 1 : 6; 2d, 1 : 8; 2e, 1 : 10).



(a)

(b)



FIGURE 4: TEM images of the PS-GNPs conjugates 2a-2e. The scale bars are 50 nm and the inset scale bars are 10 nm.

Compound	Absorption λ_{\max} (nm) (log ε)		
Compound	Soret	Qy	
1	435 (0.64)	702 (0.67)	
2a	440 (0.34)	724 (0.28)	
2b	434 (0.69)	762 (0.77)	
2c	435 (0.62)	719 (0.34)	
2d	434 (0.69)	702 (0.50)	
2e	434 (0.69)	702 (0.44)	

TABLE 1: Absorption properties of PS1 and the PS-GNPs conjugates 2a-2e.

(2.5 mL) in a 50 mL flat bottom flask and was stirred at room temperature for 2 h. The solution color was changed from yellow to greenish black, and then the solution was stored at room temperature.

Growth of PS-GNPs Conjugate. 0.001 M solution of HAuCl₄ (25 mL) is added to suitable concentration (for various molar ratios between Au(III) and PS1) of PS1 solution (25 mL) in a 250 mL flat bottom flask (the color of solution was changed from yellow to green). Then 0.005 M AgNO₃ solution (1 mL) was added to the mixture. To this mixture, the seed solution $(100 \,\mu\text{L})$ was added to the center of the solution. Then the flask was never moved, so that the seed started to grow in the growth solution. After few minutes, the each PS-GNPs conjugate was obtained and washed with water for several

times and was centrifuged at 10,000 rpm for 10 min and resuspended in water. Selected data for **2a**: UV-vis (water): λ , nm (loge) 275 (0.36), 373 (0.43), 388 (0.46), 393 (0.48), 524 (0.21), 560 (0.25), 672 (0.23), 714 (0.35). ¹H NMR (500 MHz, CD₃OD, 25°C, TMS) δ, ppm 8.91 (2H, s, H-5 and H-1 gluca), 8.74 (1H, s, H-10), 8.64 (3H, s, H-20 and H-NH gluc), 7.82 (1H, m, H-3¹), 6.21and 6.12 (2H, dd, H-3²), 4.95 (1H, m, H-18), 4.41 (1H, m, H-17), 3.62 (3H, s, H-12¹), 3.41 (2H, d, H-8¹), 3.21 (3H, s, H-2¹), 3.16 (2H, d, H-6 gluc), 2.82 (6H, s, H-7 gluc and 7¹), 2.63 (2H, m, H-17¹), 2.30 (2H, m, H-17²), 1.75 (3H, d, H-18¹), 1.33 (3H, m, H-8¹), 0.88 (1H, br s, NH), 0.08 (1H, br s, NH). ATR IR (cm⁻¹): 3400 (w, stretching $-NH_2^+$ -), 1760 (s, stretching C=O), 1525 (s), 1300-1100 (stretching, bending C=O).

2.3. Cell Culture and Photo Irradiation. A549 human lung carcinoma cell lines were obtained from the cell line bank at Seoul National University's cancer research center and were grown in medium RPMI-1640 (Sigma-Aldrich) with 10% fetal bovine serum, glutamine, penicillin, and streptomycin at 37° C in humidified atmosphere of 5% CO₂ in air. Phosphate-buffered saline (PBS) (Sigma-Aldrich), microscope (Olympus, CK40-32 PH), ELISA-reader (BioTek, SynergyHT), trypsin-EDTA, solution and incubator (37°C, 5% CO_2) were used. The PDT was carried out using a diode laser generator apparatus (BioSpec LED, Russia) equipped with a halogen lamp, a bandpass filter (640-710 nm), and



FIGURE 5: Cell viability (%) of PS1 (0–25 μ g/mL) and the PS-GNPs conjugates **2a–2e** against A549 cells by exposure to an irradiation after 3 h, 24 h, and 48 h incubation times at 670–710 nm (2 J·cm⁻²) for 15 min.

a fiber optics bundle. The duration of light irradiation, under PDT treatment, is calculated taking into account the empirically found effective dose of light energy in $J \cdot cm^2$.

2.4. MTT Assay and Cell Viability. A549 Cells (1 × 10^5 cells/well) in 100 μ L of the mixed medium were placed in a 96-well plate and incubated for 48 h (37°C, 5% CO₂). The medium was removed and the cultures were washed 3 times with physiologic saline. And the Pu-18-NMGA PS1 (0.8–25 μ g/mL) or corresponding amount of the PS-GNPs conjugates **2a–2e** (constant amount of the PS1) in 100 μ L of the mixed medium was added in each well. 24 h later, the Pu-18-NMGA PS1 or each PS-GNPs conjugate solution was discarded, and the cultures were washed 3 times with physiological saline and then medium (100 μ L/well) was added. The cultures were then subjected to the irradiation

(2 J·cm⁻²) at the distance of 20 cm for 15 min, followed by an 3-(4,5-dimethylthiazole-2-yl)-2,5-biphenyl tetrazolium bromide (MTT) assay to evaluate their sensitivity to PDT. For the MTT assay, MTT solution (10 μ L) was added to each cellculture well and cultured in the incubator for 3 h. Detergent solution (TACS, Trevigen, 200 μ L) was added to the culture, shaken for 10 min, and the absorbance was measured with an ELISA reader at 570 nm. Measurements were performed 3 h, 24 h, and 48 h incubation time after the irradiation, respectively. Each group consisted of 3 wells.

3. Results and Discussion

3.1. Preparation of Gold Nanoparticles Conjugates. The commonly used synthetic way of GNPs is a reduction method of Au(III) salt (usually from $HAuCl_4$) using sodium citrate



FIGURE 6: Comparative cell viability (%) of PS1 (3.2 μ g/mL) and the PS-GNPs conjugates **2a**–**2e** against A549 cells by photo irradiation after 3 h, 24 h, and 48 h incubation times.

in water [35]. In this method, sodium citrate has a double role as a weak reducing agent as well as a capping agent that stabilizes the NPs. The particle size is controlled by a ratio between citrate and $AuCl_4^-$ ions. Higher concentration of citrate afforded smaller particle size [35].

However, in this work, we used hydrophilic PS1 and Au(III) without any additional reducing agents and surfactants [32]. The hydroxyl groups of NMGA in PS1 have important roles as a reducing agent as well as a stabilizer through the electrically charged functional groups (i.e., carboxylate and amine groups) in forming the PS-GNPs conjugates [9]. PS1 was obtained from the carboxyl group of purpurin-18 (Pu-18) and the amine group of NMGA by simple and effective method (Figure 1). Pu-18 was synthesized from a conversion of methyl pheophorbide a (MPa) by air oxidation in npropanol with KOH [34]. MPa was obtained from Spirulina pacifica algae by the procedure reported by Smith et al. [33]. PS-GNPs conjugates were prepared from the reaction of different molar ratios between Au(III) and PS1 (2a, 1:2; 2b, 1:4; 2c, 1:6; 2d, 1:8; 2e, 1:10) in water to afford different particle sizes (Figure 2). The structures of the water soluble PS1 and the PS-GNPs conjugates were confirmed by ¹H-NMR spectroscopy, mass spectrometry, and UV-vis spectroscopy (Figure 3).

The water soluble PS1 acts not only as a reducing agent, but also as a capping agent in the reduction of $HAuCl_4$ for synthesis of PS-GNPs conjugates. The formation of PS-GNPs conjugates is stable in the aqueous solution due to the adsorption of oxidized PS1 on the surface of the GNPs through a strong coordinate-covalent bond between carboxylate on PS1 and gold metal. So the binding strength of PS1 on the GNPs surface is enough to allow accumulation of PS1 in culture medium or *in vivo* [8, 24, 36, 37]. Therefore, a large amount of water soluble PS was generally used in order to get stable GNPs. Hence, we have used five different concentration ratios between Au(III) and PS1 in order to find suitable concentration ratio that gives optimal size of the PS-GNPs conjugates for best photodynamic activity result.

3.2. UV-Vis Spectroscopic Investigation and Size Analysis by TEM Images. Figure 3 shows the UV-vis absorption spectra of the PS-GNPs conjugates **2a–2e** in water. In each conjugate, typical plasmon resonance band of the GNPs was appeared at 506–525 nm, respectively [24]. In **2a–2c**, the longest wavelength absorption (λ_{max}) is longer (719–762 nm) than that of PS1 (702 nm), while λ_{max} of **2d–2e** is the same with that of PS1 (Table 1). Among the conjugates, **2b** showed the longest wavelength absorption at 762 nm. In **2a–2b**, the Soret band at about 330–450 nm was broadened, indicating the formation of stacking structure of the chlorin ring on the gold surfaces [25].

Figure 4 shows the typical TEM images of the PS-GNPs conjugates 2a-2e prepared by using different concentration ratios between Au(III) and PS1. The images of the conjugates are different from each other in size and shape corresponding to the different molar ratios used in the preparation of the conjugates (Table 2). In 2a, when molar ratio was 1:2 for Au(III): PS1, the GNPs are mainly peanut-shaped nanocrystals in water. And some spheres have diameters around 60 nm and are well dispersed with no aggregation between the GNPs in water. In 2b, when molar ratio was 1:4, the GNPs are nanospheres have diameters around 5-11 nm. And some GNPs are closely placed each other and have a chainlike appearance with branching. In 2c, when molar ratio was 1:6, the GNPs are nanospheres have diameters around 5–10 nm. However, some GNPs are aggregated together to form many bundles of GNPs, resulting in bigger diameters around 27-44 nm. In 2d, when molar ratio was 1:8, the GNPs are mainly aggregated bundles and shape was not spheres with length around 50–90 nm and width around 25–50 nm. And yield of the GNPs was low and some aggregated GNPs have size around 200 nm. In 2e, when molar ratio was 1:10, the GNPs are mainly aggregated and yield of the GNPs was very low, and some aggregated bundles of GNPs were around 50-70 nm size. When relatively lower molar ratio of PS1 (2 or 4) made stable GNPs conjugate, however, higher molar ratio allowed unstable GNPs conjugate and remains continuous aggregation [35]. Consequently, the molar ratio between Au(III) and PS1 is an important driving force to control GNPs size, shape, and aggregation degree of the GNPs in aqueous media.

Based on the UV-vis spectra and TEM images, there is a good relationship between absorption intensity and particle size. Higher absorption intensity of the conjugate corresponds to bigger particle size. In **2a**, absorption intensity at over than 450 nm ranges is the highest among all the conjugates, which corresponds to the biggest size (about 60 nm) in the conjugates.

Compound **2b** shows the longest wavelength absorption at 762 nm which is included in NIR wavelength region (PTT therapeutic window, 750–1100 nm), so there is a potential for using PTT. We are considering that the GNPs conjugate

Compound	Shape	Diameter (nm)	Dispersion
2a	Sphere, peanut	~60	GNPs are well dispersed and showed no aggregation.
2b	Sphere, chain-like appearance with branching	5-11	GNPs are well dispersed and showed no aggregation.
2c	Sphere	5-11	Some aggregated GNPs have diameter sizes of 27-44 nm.
2d	Not sphere	_	GNPs have a lot of aggregation.
2e	Not sphere	_	Very few aggregated GNPs have sizes of 50–70 nm.

TABLE 2: Summary of TEM images of the PS-GNPs conjugates 2a-2e.



FIGURE 7: Cell viability (%) of PS1 ($0-25 \mu g/mL$) and the PS-GNPs conjugates **2a-2e** against A549 cells without photo irradiation (dark cytotoxicity) after 3 h, 24 h, and 48 h incubation times.

for a combination (synergy effect) therapy of PDT and PTT [38, 39].

3.3. Photodynamic Activity and Size Effect by In Vitro. In vitro activity of the GNPs conjugates was evaluated by comparison with PS1 against A549 human lung adenocarcinoma cells at 0.8, 1.6, 3.2, 6.1, 12.5, and $25 \,\mu$ g/mL. In this case, PS1 was dissolved in a mixed solvent of ethanol and water (1:1 volume ratio) and conjugates **2a–2e** were resuspended in

water. The dark cytotoxicity and phototoxicity of **2a-2e** and PS**1** were measured by MTT assay at 3 h, 24 h, and 48 h incubation times, respectively.

In all the compounds, upon photo irradiation, the cell viability was decreased corresponding to the increased incubation time after PDT as well as increased concentration (Figure 5), for example, at 48 h incubation and $3.2 \,\mu g/mL$, 80% at 3 h, 75% at 24 h, and 69% for PS1, and 66% at 3 h, 50% at 24 h, and 47% for **2a** (Figure 6), respectively.

TABLE 3: IC_{50} (µg/mL) values of PS1 and **2a–2e** against A549 cells at various incubation times. IC_{50} values were determined by MTT assay at 3 h, 24 h and 48 h incubation after photo irradiation.

Compound	3 h	24 h	48 h
1	14.8	10.5	8.72
2a	7.14	5.32	4.32
2b	12.06	7.24	6.38
2c	20.53	14.43	13.05
2d	20.52	18.51	12.95
2e	24.23	22.12	11.82

Dark cytotoxicity of PS1 and conjugates 2a-2e is shown in Figure 7. At highest concentration (25 μ g/mL) with 48 h incubation time, all compounds showed high dark cytotoxicity (cell viability 32–61%).

PS1 showed slightly higher photocytotoxicity (IC₅₀, $10.5 \,\mu\text{g/mL} = 14 \,\mu\text{M}$ at 24 h incubation time) than that of the purpurin-18-choline derivative (IC₅₀, $15 \,\mu\text{M}$ at 24 h incubation time) that has been previously reported by us [25]. Conjugates 2a and 2b showed higher photocytotoxicity than that of PS1. At high concentration (e.g., at $25 \,\mu g/mL$), 2a showed higher dark cytotoxicity (69% at 3 h, 49% at 24 h, and 48% at 48 h incubation time, Figure 7) as compared to PS1 (62% at 3 h, 60% at 24 h, and 56% at 48 h incubation time), which might be attributed to large amount of PS1 molecules on the GNPs surface in 2a. However, conjugates 2c–2e showed lower photocytotoxicity than that of PS1. This result demonstrates that photodynamic activity significantly depends on size and aggregation degree of the GNPs. For example, in **2a** and **2b** there is no aggregation between each other and 2a has about 60 nm size, while in 2c-2e there are some aggregated bundles of the GNPs with small size. Chithrani et al. [29] studied a relationship between particles size (14-100 nm) and cellular uptake of the GNPs in HeLa cells, in which the maximum uptake was occurred at a size of 50 nm. Jiang et al. [28] have reported that cellular uptake strongly depends on the size of the GNPs, in which the GNPs having 2-100 nm size range were coated with Herceptin and were evaluated for cell internalization against breast cancer cell lines by the ErbB2 receptor. The most efficient cellular uptake was observed with particles range of 20-50 nm. Apoptosis was also enhanced by the GNPs having 40-50 nm size [28]. From the high dark cytotoxicity at high concentration, we confirmed that the PS-GNPs conjugate 2a and 2b showed better photodynamic activity at low concentration $(3.2 \,\mu\text{g/mL})$ having low dark cytotoxicity (Figure 7).

In addition, **2a** and **2b** have higher absorbance at irradiated wavelength range, which allowed good photodynamic activity results. In **2c–2e**, absorption intensity was lower than that of PS1, resulting in lower photocytotoxicity as compared to PS1. Table 3 shows the IC₅₀ values for PS1 and its PS-GNPs conjugates **2a–2e**. At 48 h incubation time, **2a** and **2b** showed better IC₅₀ value, 4.32 and 6.38 μ g/mL, respectively, as compared to PS1 (8.72 μ g/mL). Therefore, as we pointed out above, photodynamic *in vitro* activity of synthesized PS-GNPs conjugates (**2a** and **2b**) is much higher than that of the free PS1. This result indicates that optimal size and welldispersed nanoparticles are important for photodynamic effect in aqueous media. Especially, bigger size (~60 nm) of nanoparticles **2a** could be useful to transport more chlorine molecules into the cancer cells by endocytosis [28, 29, 40].

4. Conclusions

In summary, a simple single-step synthesis of PS-GNPs conjugates from different molar ratios of Au(III)/water soluble ionic PS1 (purpurin-18-N-methyl-D-glucamine) has been studied without adding any particular reducing agents and surfactants. In vitro anticancer efficacy of the PS-GNPs conjugates against A549 lung cancer cell lines was evaluated. We revealed that PDT in vitro activity of synthesized PS-GNPs conjugates was higher as compared to free PS1 because of good transport of the PS into the cells by using size effect. Conjugate 2a based on molar ratio between HAuCl₄ and PS was 1:2 that exhibits best PDT efficiency than other conjugates having different molar ratios. This result could be useful for synthesis of new PS and PS-GNPs conjugates having different size as well as for developing good relationship between PDT activity and size effect of GNPs in aqueous media.

Conflict of Interests

We do not have any conflict of interests to Sigma-Aldrich and BioSpec LED.

Acknowledgments

This research was supported by the BK21 Project and the National Research Foundation (NRF) of Korea. The grant funded by the Ministry of Education, Science and Technology (NRF-2011-0007082 and NRF-2009-353-C00055).

References

- R. K. Pandey, L. N. Goswami, Y. Chen et al., "Nature: a rich source for developing multifunctional agents. Tumor-imaging and photodynamic therapy," *Lasers in Surgery and Medicine*, vol. 38, no. 5, pp. 445–467, 2006.
- [2] R. Bonnet, Chemical Aspects of Photodynamic Therapy, Gordon and Breach Science Publishers, Amsterdam, The Netherlands, 2000.
- [3] R. K. Pandey and G. Zheng, "In porphyrins as photosensitizers in photodynamic therapy," in *The Porphyrin Handbook*, Kadish, Smith, and Guilard, Eds., vol. 6, pp. 157–230, Academic Press, New York, NY, USA, 2000.
- [4] S. Wang, R. Gao, F. Zhou, and M. Selke, "Nanomaterials and singlet oxygen photosensitizers: potential applications in photodynamic therapy," *Journal of Materials Chemistry*, vol. 14, no. 4, pp. 487–493, 2004.
- [5] G. F. Paciotti, D. G. I. Kingston, and L. Tamarkin, "Colloidal gold nanoparticles: a novel nanoparticle platform for developing multifunctional tumor-targeted drug delivery vectors," *Drug Development Research*, vol. 67, no. 1, pp. 47–54, 2006.

- [6] M. K. Khaing Oo, X. Yang, H. Du, and H. Wang, "5aminolevulinic acid-conjugated gold nanoparticles for photodynamic therapy of cancer," *Nanomedicine*, vol. 3, no. 6, pp. 777–786, 2008.
- [7] M. Olivo, R. Bhuvaneswari, S. S. Lucky, N. Dendukuri, and P. S.-P. Thong, "Targeted therapy of cancer using photodynamic therapy in combination with multi-faceted anti-tumor modalities," *Pharmaceuticals*, vol. 3, no. 5, pp. 1507–1529, 2010.
- [8] D. Pissuwan, T. Niidome, and M. B. Cortie, "The forthcoming applications of gold nanoparticles in drug and gene delivery systems," *Journal of Controlled Release*, vol. 149, no. 1, pp. 65–71, 2011.
- [9] B. Pegaz, E. Debefve, F. Borle et al., "Preclinical evaluation of a novel water-soluble Chlorin e6 derivative (BLC 1010) as photosensitizer for the closure of the neovessels," *Photochemistry and Photobiology*, vol. 81, no. 6, pp. 1505–1510, 2005.
- [10] G.-I. Sengee, N. Badraa, and Y. K. Shim, "Synthesis and biological evaluation of new imidazolium and piperazinium salts of pyropheophorbide-a for photodynamic cancer therapy," *International Journal of Molecular Sciences*, vol. 9, no. 8, pp. 1407–1415, 2008.
- [11] W. S. L. Strauss, R. Sailer, H. Schneckenburger et al., "Photodynamic efficacy of naturally occurring porphyrins in endothelial cells in vitro and microvasculature in vivo," *Journal of Photochemistry and Photobiology B*, vol. 39, no. 2, pp. 176–184, 1997.
- [12] S. Wang, R. Gao, F. Zhou, and M. Selke, "Nanomaterials and singlet oxygen photosensitizers: potential applications in photodynamic therapy," *Journal of Materials Chemistry*, vol. 14, no. 4, pp. 487–493, 2004.
- [13] L. Wang, J. Bai, Y. Li, and Y. Huang, "Multifunctional nanoparticles displaying magnetization and near-IR absorption," *Angewandte Chemie International Edition*, vol. 47, no. 13, pp. 2439–2442, 2008.
- [14] S. Jelveh and D. B. Chithrani, "Gold nanostructures as a platform for combinational therapy in future cancer therapeutics," *Cancers*, vol. 3, no. 1, pp. 1081–1110, 2011.
- [15] Y. Matsumura and H. Maeda, "A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs," *Cancer Research*, vol. 46, no. 12, part 1, pp. 6387–6392, 1986.
- [16] V. P. Torchilin, "Multifunctional nanocarriers," Advanced Drug Delivery Reviews, vol. 58, no. 14, pp. 1532–1555, 2006.
- [17] P. A. Vasey, S. B. Kaye, R. Morrison et al., "Phase I clinical and pharmacokinetic study of PK1 [N-(2- hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents—drug-polymer conjugates," *Clinical Cancer Research*, vol. 5, no. 1, pp. 83–94, 1999.
- [18] P. K. Jain, X. Huang, I. H. El-Sayed, and M. A. El-Sayed, "Noble metals on the nanoscale: optical and photothermal properties and some applications in imaging, sensing, biology, and medicine," *Accounts of Chemical Research*, vol. 41, no. 12, pp. 1578–1586, 2008.
- [19] X. Huang, I. H. El-Sayed, W. Qian, and M. A. El-Sayed, "Cancer cell imaging and photothermal therapy in the nearinfrared region by using gold nanorods," *Journal of the American Chemical Society*, vol. 128, no. 6, pp. 2115–2120, 2006.
- [20] J. Kim, S. Park, J. E. Lee et al., "Designed fabrication of multifunctional magnetic gold nanoshells and their application

to magnetic resonance imaging and photothermal therapy," *Angewandte Chemie International Edition*, vol. 45, no. 46, pp. 7754–7758, 2006.

- [21] J. Nam, N. Won, H. Jin, H. Chung, and S. Kim, "pH-induced aggregation of gold nanoparticles for photothermal cancer therapy," *Journal of the American Chemical Society*, vol. 131, no. 38, pp. 13639–13645, 2009.
- [22] M. E. Wieder, D. C. Hone, M. J. Cook, M. M. Handsley, J. Gavrilovic, and D. A. Russell, "Intracellular photodynamic therapy with photosensitizer-nanoparticle conjugates: cancer therapy using a 'Trojan horse," *Photochemical & Photobiological Sciences*, vol. 5, no. 8, pp. 727–734, 2006.
- [23] N. Narband, S. Tubby, I. P. Parkin et al., "Gold nanoparticles enhance the toluidine blue-induced lethal photosensitisation of Staphylococcus aureus," *Current Nanoscience*, vol. 4, no. 4, pp. 409–414, 2008.
- [24] Y. Cheng, A. C. Samia, J. D. Meyers, I. Panagopoulos, B. Fei, and C. Burda, "Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer," *Journal of the American Chemical Society*, vol. 130, no. 32, pp. 10643–10647, 2008.
- [25] D. Demberelnyamba, M. Ariunaa, and Y. K. Shim, "Newly synthesized water soluble Cholinium-Purpurin photosensitizers and their stabilized gold nanoparticles as promising anticancer agents," *International Journal of Molecular Sciences*, vol. 9, no. 5, pp. 864–871, 2008.
- [26] N. F. Gamaleia, E. D. Shishko, G. A. Dolinsky, A. B. Shcherbakov, A. V. Usatenko, and V. V. Kholin, "Photodynamic activity of hematoporphyrin conjugates with gold nanoparticles: experiments in vitro," *Experimental Oncology*, vol. 32, no. 1, pp. 44–47, 2010.
- [27] X. Liu, M. Atwater, J. Wang, and Q. Huo, "Extinction coefficient of gold nanoparticles with different sizes and different capping ligands," *Colloids and Surfaces B*, vol. 58, no. 1, pp. 3–7, 2007.
- [28] W. Jiang, B. Y. S. Kim, J. T. Rutka, and W. C. W. Chan, "Nanoparticle-mediated cellular response is size-dependent," *Nature Nanotechnology*, vol. 3, no. 3, pp. 145–150, 2008.
- [29] B. D. Chithrani, A. A. Ghazani, and W. C. W. Chan, "Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells," *Nano Letters*, vol. 6, no. 4, pp. 662–668, 2006.
- [30] X. Ma, Y. Wu, S. Jin et al., "Gold nanoparticles induce autophagosome accumulation through size-dependent nanoparticle uptake and lysosome impairment," ACS Nano, vol. 5, no. 11, pp. 8629–8639, 2011.
- [31] Y. Shan, S. Ma, L. Nie et al., "Size-dependent endocytosis of single gold nanoparticles," *Chemical Communications*, vol. 47, no. 28, pp. 8091–8093, 2011.
- [32] B. Lkhagvadulam, J. H. Kim, I. Yoon, and Y. K. Shim, "Synthesis and photodynamic activities of novel water soluble purpurin-18-N-methyl-D-glucamine photosensitizer and its gold nanoparticles conjugate," *Journal of Porphyrins and Phthalocyanines*, vol. 16, no. 4, pp. 331–340, 2012.
- [33] K. M. Smith, D. A. Goff, and D. J. Simpson, "The meso substitution of chlorophyll derivatives: direct route for transformation of bacteriopheophorbides d into bacteriopheophorbides c," *Journal of the American Chemical Society*, vol. 107, no. 17, pp. 4946–4954, 1985.
- [34] G. Zheng, W. R. Potter, S. H. Camacho et al., "Synthesis, photophysical properties, tumor uptake, and preliminary in

vivo photosensitizing efficacy of a homologous series of 3-(1'-alkyloxy)-ethyl-3-devinylpurpurin-18-N-alkylimides with variable lipophilicity," *Journal of Medicinal Chemistry*, vol. 44, no. 10, pp. 1540–1559, 2001.

- [35] T. Kim, K. Lee, M.-S. Gong, and S.-W. Joo, "Control of gold nanoparticle aggregates by manipulation of interparticle interaction," *Langmuir*, vol. 21, no. 21, pp. 9524–9528, 2005.
- [36] Y.-H. Chen, C.-Y. Tsai, P.-Y. Huang et al., "Methotrexate conjugated to gold nanoparticles inhibits tumor growth in a syngeneic lung tumor model," *Molecular Pharmaceutics*, vol. 4, no. 5, pp. 713–722, 2007.
- [37] Y. Cheng, J. D. Meyers, A.-M. Broome, M. E. Kenney, J. P. Basilion, and C. Burda, "Deep penetration of a PDT drug into tumors by noncovalent drug-gold nanoparticle conjugates," *Journal of the American Chemical Society*, vol. 133, no. 8, pp. 2583–2591, 2011.
- [38] J. C. Y. Kah, R. C. Y. Wan, K. Y. Wong, S. Mhaisalkar, C. J. R. Sheppard, and M. Olivo, "Combinatorial treatment of photothermal therapy using gold nanoshells with conventional photodynamic therapy to improve treatment efficacy: an in vitro study," *Lasers in Surgery and Medicine*, vol. 40, no. 8, pp. 584–589, 2008.
- [39] W.-S. Kuo, C.-N. Chang, Y.-T. Chang et al., "Gold nanorods in photodynamic therapy, as hyperthermia agents, and in nearinfrared optical imaging," *Angewandte Chemie International Edition*, vol. 49, no. 15, pp. 2711–2715, 2010.
- [40] X.-M. Jiang, L.-M. Wang, and C.-Y. Chen, "Cellular uptake, intracellular trafficking and biological responses of gold nanoparticles," *Journal of the Chinese Chemical Society*, vol. 58, no. 3, pp. 273–281, 2011.



BioMed Research International









International Journal of Genomics











The Scientific World Journal



Genetics Research International



Anatomy Research International



International Journal of Microbiology



Biochemistry Research International



Journal of Marine Biology







International Journal of Evolutionary Biology



Molecular Biology International